Amphix Bio awarded grant from Reeve Foundation and Spinal Research
January 6, 2026
Amphix Bio has received a research grant co-sponsored by the Christopher & Dana Reeve Foundation and Spinal Research to test AMFX-200, the company’s lead Supramolecular Therapeutic Peptide (STP) candidate, in combination with structured physical rehabilitation in both acute and chronic spinal cord injury (SCI) models.
Physical rehabilitation is the standard of care for people living with SCI and can influence functional recovery. However, it is difficult to replicate in preclinical settings, creating a critical barrier to translating regenerative therapies from the lab to the clinic.
​
​
​
_edited_edited.jpg)
To address this challenge, Amphix Bio will partner with researchers at the Center for Regenerative Nanomedicine (CRN) at Northwestern University to study how treatment with AMFX-200 interacts with physical rehabilitation training in preclinical models of spinal cord injury. The research will generate insights that better reflect the realities of patient recovery and clinical outcomes.
​
“Our mission is deeply aligned with that of the Reeve Foundation and Spinal Research, which is to support patients and families living with spinal cord injury,” said Samuel Stupp, PhD, Co-founder and Chief Scientific Officer of Amphix Bio. “This grant allows us to mirror the real-world recovery that impacts the daily lives and long-term outcomes of patients.”
This award builds on Amphix Bio’s recently announced $12.5 million seed financing round and follows several other milestones for its spinal cord injury program. The company completed a Type C meeting with the U.S. Food and Drug Administration, receiving constructive feedback on the AMFX-200 development program, and recently secured Orphan Drug Designation for treatment of acute spinal cord injury.
Read the full announcement from the Reeve Foundation and Spinal Research.